Advertisement
FHI vs IVZ
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FHI is a Buy and IVZ is a Hold.
FHI's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for FHI moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In 13 of the 17 cases the stock moved higher. This puts the odds of a move higher at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 49 cases where FHI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for FHI just turned positive on October 15, 2026. Looking at past instances where FHI's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
Following a +1.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHI advanced for three days, in 205 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
FHI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FHI as a result. In 52 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.
The 10-day moving average for FHI crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Aroon Indicator for FHI entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. FHI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.293) is normal, around the industry mean (2.352). P/E Ratio (10.270) is within average values for comparable stocks, (-5.021). Projected Growth (PEG Ratio) (1.398) is also within normal values, averaging (1.319). Dividend Yield (0.028) settles around the average of (0.271) among similar stocks. P/S Ratio (2.143) is also within normal values, averaging (15.798).
IVZ in -4.54% downward trend, declining for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IVZ declined for three days, in 196 of 282 cases, the price declined further within the following month. The odds of a continued downward trend are 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVZ as a result. In 57 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
IVZ moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IVZ crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for IVZ entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IVZ's RSI Oscillator exited the oversold zone, 28 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 56 cases where IVZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +1.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in 229 of 333 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
IVZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating fairly steady price growth. IVZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.254) is normal, around the industry mean (2.352). P/E Ratio (-42.224) is within average values for comparable stocks, (-5.021). Projected Growth (PEG Ratio) (0.901) is also within normal values, averaging (1.319). Dividend Yield (0.030) settles around the average of (0.271) among similar stocks. P/S Ratio (1.981) is also within normal values, averaging (15.798).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
FHI | IVZ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 12 | 51 | |
SMR RATING 1..100 | 31 | 92 | |
PRICE GROWTH RATING 1..100 | 50 | 52 | |
P/E GROWTH RATING 1..100 | 51 | 99 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IVZ's Valuation (75) in the Investment Managers industry is in the same range as FHI (89) in the null industry. This means that IVZ’s stock grew similarly to FHI’s over the last 12 months.
FHI's Profit vs Risk Rating (12) in the null industry is somewhat better than the same rating for IVZ (51) in the Investment Managers industry. This means that FHI’s stock grew somewhat faster than IVZ’s over the last 12 months.
FHI's SMR Rating (31) in the null industry is somewhat better than the same rating for IVZ (92) in the Investment Managers industry. This means that FHI’s stock grew somewhat faster than IVZ’s over the last 12 months.
FHI's Price Growth Rating (50) in the null industry is in the same range as IVZ (52) in the Investment Managers industry. This means that FHI’s stock grew similarly to IVZ’s over the last 12 months.
FHI's P/E Growth Rating (51) in the null industry is somewhat better than the same rating for IVZ (99) in the Investment Managers industry. This means that FHI’s stock grew somewhat faster than IVZ’s over the last 12 months.
| FHI | IVZ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 52% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 65% | N/A |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 69% |
| Advances ODDS (%) | 12 days ago 62% | 19 days ago 69% |
| Declines ODDS (%) | 2 days ago 52% | 7 days ago 70% |
| BollingerBands ODDS (%) | 5 days ago 74% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FHI’s FA Score shows that 2 FA rating(s) are green while IVZ’s FA Score has 0 green FA rating(s).
- FHI’s FA Score: 2 green, 3 red.
- IVZ’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FHI’s TA Score shows that 5 TA indicator(s) are bullish while IVZ’s TA Score has 4 bullish TA indicator(s).
- FHI’s TA Score: 5 bullish, 4 bearish.
- IVZ’s TA Score: 4 bullish, 5 bearish.
Price Growth
FHI (@Investment Managers) experienced а -1.39% price change this week, while IVZ (@Investment Managers) price change was -3.32% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was +49.75%. For the same industry, the average monthly price growth was +21.94%, and the average quarterly price growth was +17.22%.
Reported Earning Dates
FHI is expected to report earnings on Oct 29, 2026.
IVZ is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Investment Managers (+49.75% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QQXL | 54.59 | 1.40 | +2.64% |
| ProShares Ultra QQQ Top 30 (QQXL) | |||
| IVVB | 35.55 | 0.11 | +0.32% |
| iShares Large Cap Deep Quarterly Laddered ETF (IVVB) | |||
| SNPE | 70.08 | 0.21 | +0.30% |
| Xtrackers S&P 500 Scored & Screened ETF (SNPE) | |||
| VGSR | 10.58 | -0.10 | -0.96% |
| Vert Global Sustainable Real Estate ETF (VGSR) | |||
| DUSL | 73.19 | -1.23 | -1.65% |
| Direxion Daily Industrials Bull 3X ETF (DUSL) | |||
What is Form 706 GS (D): Generation Skipping Transfer Tax Return for Distributions?
Are Certificates of Deposit a Secure Avenue for Your Savings?
DeFi Development (DFDV) Stock Analysis: A Stellar Performer in 2025
FAQ: How does the Tickeron AI Screener function?
Analysis of Top Consumer Electronics and Appliance Stocks
FHI and
Correlation & Price change
A.I.dvisor indicates that over the last year, FHI has been loosely correlated with IVZ. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FHI jumps, then IVZ could also see price increases.
| Ticker / NAME | Correlation To FHI | 1D Price Change % | ||
|---|---|---|---|---|
| FHI | 100% | -1.22% | ||
| IVZ - FHI | 58% Loosely correlated | +0.32% | ||
| BLK - FHI | 57% Loosely correlated | -0.86% | ||
| BEN - FHI | 57% Loosely correlated | -0.87% | ||
| VRTS - FHI | 57% Loosely correlated | -4.22% | ||
| APAM - FHI | 56% Loosely correlated | -0.81% | ||
More | ||||
IVZ and
Correlation & Price change
A.I.dvisor indicates that over the last year, IVZ has been closely correlated with BLK. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if IVZ jumps, then BLK could also see price increases.